Non-Viral Nucleic Acid Delivery Strategies to the Central Nervous System
- PMID: 27847462
- PMCID: PMC5088201
- DOI: 10.3389/fnmol.2016.00108
Non-Viral Nucleic Acid Delivery Strategies to the Central Nervous System
Abstract
With an increased prevalence and understanding of central nervous system (CNS) injuries and neurological disorders, nucleic acid therapies are gaining promise as a way to regenerate lost neurons or halt disease progression. While more viral vectors have been used clinically as tools for gene delivery, non-viral vectors are gaining interest due to lower safety concerns and the ability to deliver all types of nucleic acids. Nevertheless, there are still a number of barriers to nucleic acid delivery. In this focused review, we explore the in vivo challenges hindering non-viral nucleic acid delivery to the CNS and the strategies and vehicles used to overcome them. Advantages and disadvantages of different routes of administration including: systemic injection, cerebrospinal fluid injection, intraparenchymal injection and peripheral administration are discussed. Non-viral vehicles and treatment strategies that have overcome delivery barriers and demonstrated in vivo gene transfer to the CNS are presented. These approaches can be used as guidelines in developing synthetic gene delivery vectors for CNS applications and will ultimately bring non-viral vectors closer to clinical application.
Keywords: central nervous system; delivery; in vivo; non-viral; nucleic acid.
Figures


Similar articles
-
Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies.J Control Release. 2022 Dec;352:121-145. doi: 10.1016/j.jconrel.2022.10.018. Epub 2022 Oct 19. J Control Release. 2022. PMID: 36252748 Review.
-
Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors.Brain Res Bull. 2019 Aug;150:216-230. doi: 10.1016/j.brainresbull.2019.05.024. Epub 2019 Jun 5. Brain Res Bull. 2019. PMID: 31173859 Free PMC article. Review.
-
Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: formulating the solution.J Pharm Sci. 2013 Oct;102(10):3469-84. doi: 10.1002/jps.23672. Epub 2013 Jul 26. J Pharm Sci. 2013. PMID: 23893329 Review.
-
Localised non-viral delivery of nucleic acids for nerve regeneration in injured nervous systems.Exp Neurol. 2019 Sep;319:112820. doi: 10.1016/j.expneurol.2018.09.003. Epub 2018 Sep 6. Exp Neurol. 2019. PMID: 30195695 Review.
-
Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.Clin Pharmacokinet. 2001;40(12):907-46. doi: 10.2165/00003088-200140120-00003. Clin Pharmacokinet. 2001. PMID: 11735609 Review.
Cited by
-
Battling Neurodegenerative Diseases with Adeno-Associated Virus-Based Approaches.Viruses. 2020 Apr 18;12(4):460. doi: 10.3390/v12040460. Viruses. 2020. PMID: 32325732 Free PMC article. Review.
-
Chitosan-Based Non-viral Gene and Drug Delivery Systems for Brain Cancer.Front Neurol. 2020 Jul 30;11:740. doi: 10.3389/fneur.2020.00740. eCollection 2020. Front Neurol. 2020. PMID: 32849207 Free PMC article. Review.
-
Non-Viral Delivery of RNA Gene Therapy to the Central Nervous System.Pharmaceutics. 2022 Jan 11;14(1):165. doi: 10.3390/pharmaceutics14010165. Pharmaceutics. 2022. PMID: 35057059 Free PMC article. Review.
-
Evaluation of Poly(N-Ethyl Pyrrolidine Methacrylamide) (EPA) and Derivatives as Polymeric Vehicles for miRNA Delivery to Neural Cells.Pharmaceutics. 2023 May 10;15(5):1451. doi: 10.3390/pharmaceutics15051451. Pharmaceutics. 2023. PMID: 37242702 Free PMC article.
-
Design of a Lentiviral Vector for the Inducible Expression of MYC: A New Strategy for Construction Approach.Mol Biotechnol. 2017 Jun;59(6):200-206. doi: 10.1007/s12033-017-0006-y. Mol Biotechnol. 2017. PMID: 28447263
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources